Research demonstrating the remarkable cancer-killing power of genetically rewired white blood cells — known as CAR-T therapy — has long grabbed the spotlight at the annual meeting of the American Society of Hematology.

This year, though, the debate is no longer about whether or not CAR-T kills cancer. New research to be presented at the conference, kicking off Saturday in Atlanta, will focus instead on the long-term durability of CAR-T, the potential to target different types of blood cancers, and the feasibility of treating large numbers of patients scattered across the globe.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy